Schedule 13G/A
AKRO Schedule 13G/A filing by T. Rowe Price Associates
T. Rowe Price Associates reported beneficial ownership of 3.8M shares, representing 12% of AKERO THERAPEUTICS INC in this filing.
FiledNov 14, 2025
Ownership dateSep 30, 2025
Reported shares3.8M
Reported ownership12%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
3.7M
Shared voting power
3.8M
Sole dispositive power
3.8M
Shared dispositive power
3.8M
Compared with the prior filing
How the reported position changed
This compares the current filing with the previous tracked Schedule 13 filing from the same reporting CIK for AKRO. A change between filings does not by itself establish when shares were bought or sold.
Previous filingNov 14, 2024
Reported share change+1,717
Ownership percentage change+6.5 pts
| Previous filing | This filing | |
|---|---|---|
| Reported shares | 3.8M | 3.8M |
| Reported ownership | 5.5% | 12% |
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- T. Rowe Price Associates
- CIK
- CIK0000080255
- Accession
- 0000080255-25-000832
- Form
- Schedule 13G/A
Read the filing in context